ArticleBMC dermatology2018
Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India).
Article in BMC dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Efficacy and Safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Pedis: A Phase III Randomised, Double-Blind, Parallel-Group, Active-Controlled Study in Indian Adult Patients.Clinical drug investigation · 2023Trial
- Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.Drug design, development and therapy · 2023Trial
- Microsporum canis complex infections in the United Arab Emirates: Clinical, molecular, and antifungal susceptibility profiles.Medical mycology · 2026Article
- The natural history and evolution of dermatophytosis: Host immunity in acute and chronic infection.PLoS pathogens · 2026Article
- Review
- Dermatophytosis in Iran: a sharp increase in cases caused byIMA fungus · 2026Article
- Mental Health and Quality of Life in Chronic and Recurrent vs First-Episode Dermatophytosis: A Cross-Sectional Study.Consortium psychiatricum · 2026Article
- Global Emergence ofInfection and drug resistance · 2026Review
- Resistance & virulence traits in dermatophytes isolated from Mangaluru, India.The Indian journal of medical research · 2025Article
- Patients knowledge attitudes and practices regarding superficial fungal infections suggest public health and patient education are warranted.Scientific reports · 2025Article
- Article
- NEXTODERM: Consensus on Dermatophytosis Diagnosis and Management in Nepal.Dermatology research and practice · 2025Review
- Clinical and Microbiological Spectrum of Dermatophytosis From a Tertiary Care Institute.Cureus · 2025Article
- Over the counter use of topical corticosteroid for skin conditions among patients before attending skin specialist clinic in Nepal: A qualitative study.PLOS global public health · 2025Article
- Dermatophytes: Update on Clinical Epidemiology and Treatment.Mycopathologia · 2024Review
- Tinea Incognito: Challenges in Diagnosis and Management.Journal of clinical medicine · 2024Review
- Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance.American journal of clinical dermatology · 2024Review
- Diagnosis of a recurred lesion in dermatophytosis patients after 2 weeks of antifungal therapy: A prospective observational study.Journal of family medicine and primary care · 2024Article
- A systematic analysis of the global, regional, and national burden of fungal skin diseases from 1990 to 2021.Frontiers in epidemiology · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDermatophytosis management has become an important public health issue, with a large void in research in the area of disease pathophysiology and management. Current treatment recommendations appear to lose their relevance in the current clinical scenario. The objective of the current consensus was to provide an experience-driven approach regarding the diagnosis and management of tinea corporis, cruris and pedis.
methodsEleven experts in the field of clinical dermatology and mycology participated in the modified Delphi process consisting of two workshops and five rounds of questionnaires, elaborating definitions, diagnosis and management. Panel members were asked to mark "agree" or "disagree" beside each statement, and provide comments. More than 75% of concordance in response was set to reach the consensus.
resultKOH mount microscopy was recommended as a point of care testing. Fungal culture was recommended in chronic, recurrent, relapse, recalcitrant and multisite tinea cases. Topical monotherapy was recommended for naïve tinea cruris and corporis (localised) cases, while a combination of systemic and topical antifungals was recommended for naïve and recalcitrant tinea pedis, extensive lesions of corporis and recalcitrant cases of cruris and corporis. Because of the anti-inflammatory, antibacterial and broad spectrum activity, topical azoles should be preferred. Terbinafine and itraconazole should be the preferred systemic drugs. Minimum duration of treatment should be 2-4 weeks in naïve cases and > 4 weeks in recalcitrant cases. Topical corticosteroid use in the clinical practice of tinea management was strongly discouraged.
conclusionThis consensus guideline will help to standardise care, provide guidance on the management, and assist in clinical decision-making for healthcare professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.